Ethylparaben induces subconjunctival fibrosis via the Wnt/β‑catenin signaling pathway

  • Authors:
    • Fengge Liu
    • Xiangfeng Kong
    • Hui Kong
  • View Affiliations

  • Published online on: January 28, 2021     https://doi.org/10.3892/etm.2021.9726
  • Article Number: 295
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to explore the etiology of subconjunctival fibrosis (SCF) induced by ethylparaben, the most prevalent preservative in Chinese eye drops. Ethylparaben was administered to the left eyes of male Sprague‑Dawley rats in the experimental group twice daily for 1 month, whereas the control group received PBS. Experimental group rats displayed a mild promotion in density of fibroblasts and a tighter deposition of collagen in the bulbar subepithelial connective tissue compared with the control group. Furthermore, the present findings revealed that extracellular matrix expression was promoted in murine bulbar conjunctival tissues in the experimental group. In primary conjunctival fibroblasts, expression of ECM triggered by ethylparaben was suppressed by XAV‑939. Furthermore, stimulation of the Wnt/β‑catenin axis triggered by ethylparaben was impaired by XAV‑939. In conclusion, SCF triggered by ethylparaben results from extra ECM generation of conjunctival fibroblasts via the Wnt/β‑catenin axis.

Introduction

Ethylparaben is a widely used preservative in Chinese eye drops (1,2). Subconjunctival fibrosis (SCF) leads to failure of glaucoma filtration surgery, inducing conjunctival scarring during wound healing (3-5). Nevertheless, the action of ethylparaben in SCF remains to be elucidated.

The Wnt/β-catenin axis participates in development and in tissue homeostasis, and is divided into canonical and non-canonical signaling (6,7). Abnormal stimulation of the canonical Wnt pathway stimulates various pathological states including malignancies (8). The transcription factor complex, consisting of β-catenin, T cell factor and lymphoid enhancer factor, is widely recognized as the main modulator of the Wnt/β-catenin axis (9,10). When the Wnt ligand is not activated, a destroying complex consisting of the tumor suppressor adenomatous polyposis coli, axin and glycogen synthase kinase-3 (GSK3β) anchors cytoplasmic β-catenin (11-13). GSK3β and casein kinase 1 participate in the phosphorylation of cytoplasmic β-catenin, bringing about ubiquitination and degeneration of proteasome (14,15). When the Wnt ligand is activated, it links with the Frizzled receptor and its co-receptor, low-density lipoprotein, by a receptor-related protein 5/6 on the surface of the cell. This propels dishevelled to attract GSK3β and Axin, consequently separating β-catenin from the destroying complex (16,17). Degeneration and phosphorylation of β-catenin is subsequently suppressed prior to aggregation of cytoplasmic β-catenin and nuclear translocation (18). This association induces the expression of target genes in the Wnt/β-catenin axis. Previous studies have demonstrated that the Wnt/β-catenin axis participates in corneal fibrosis (19,20). Nevertheless, the current understanding of the influence of stimulation of the Wnt/β-catenin axis on SCF triggered by ethylparaben is insufficient.

The present study explored the etiology of SCF triggered by ethylparaben through examination of the concentration of the extracellular matrix (ECM) and agents linked with the Wnt/β-catenin axis in vivo and in vitro. It was discovered that deposition of collagen in murine conjunctival subepithelium was triggered by ethylparaben supplemented for one month, and that the Wnt/β-catenin axis was crucial to this reaction.

Materials and methods

Materials

Dulbecco's Modified Eagle Medium (DMEM) and fetal bovine serum (FBS) were purchased from Invitrogen; Thermo Fisher Scientific, Inc. (Waltham, MA, USA). Ethylparaben was provided by Sigma-Aldrich; Merck KGaA (Darmstadt, Germany). XAV-939 was obtained from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA) and used at 1 µM.

Animals and ethylparaben treatment

Experiments involving animal subjects in the present study were conducted in accordance with the internationally accepted principles for laboratory animal use and care. The present study was approved by the Committee on the Ethics of Animal Experiments of Zoucheng People's Hospital (Zoucheng, China). Sprague-Dawley rats (age, 6 weeks; weight, 215±30 g) were obtained from the Beijing Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China) and used in the present study. Rats were housed in microisolator cages in a room illuminated from 0700-1900 h (12-h light/dark cycle; humidity, 55±5%; 25±2˚C), with ad libitum access to water and chow. Animal procedures were carried out in conformity to guidelines of the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research (21). Each rat was verified for ocular surface illness prior to experimentation. A total of 18 rats were randomized into 3 groups (n=6/group). In the first group, 0.01% ethylparaben in PBS was dropped locally into the left eye (twice daily, 10 µl each). In the second group (control group), PBS was supplemented the same way (twice daily, 10 µl each). All rats were executed 1 month following supplementation. Bulbar conjunctival tissues (BCTs) were excised to separate RNA and protein. Rats in the third group received no treatment prior to sacrifice and their left eyes were enucleated under aseptic circumstances for separation of bulbar subconjunctival tissues (BSTs).

Cultivation of primary conjunctival fibroblasts (CFs)

Primary CFs were separated from BSTs and cultivated. BSTs separated under aseptic circumstances were washed thrice with PBS. BSTs were subsequently processed into 2x2-mm explants, which were planted in cultivating plates at a density of 5x103 cells/well filled with DMEM and 10% FBS and were incubated in an environment with 5% CO2, 95% humidity, and 37˚C. The medium was replaced every three days. CFs were subcultivated with trypsin for procedures between passages five and seven.

In order to examine the influence of low levels of ethylparaben on CF survival and to explore the optimal ethylparaben level for examining the etiology of ECM gene expression of CFs activated by ethylparaben, CFs were planted in plates with 96 wells (3x103 cells/well) and received media with either ethylparaben (0.000005%, 0.00001%, 0.00003%, 0.00005%, 0.0001%, 0.001%) or PBS at 37˚C.

Analysis of β-catenin nuclear translocation

CFs were treated with ethylparaben for 4 h. Nuclear fractionation was used to analyze β-catenin nuclear translocation. Briefly, nuclear extracts were isolated from CFs treated in 75-cm2 flasks using the NEPER Nuclear/Cytoplasmic Extraction Kit (Thermo Fisher Scientific, Inc.) according to the manufacturer's instructions, and analyzed by β-catenin WB analysis.

Western blotting (WB)

Western blotting was performed as previously detailed (22-24). The total proteins were extracted from BCTs, and the CFs were extracted using a cold radioimmunoprecipitation assay buffer that contains a proteinase inhibitor cocktail (Roche Diagnostics, Basel, Switzerland). Protein concentration was determined using a Piece BCA Protein Assay kit (Thermo Fisher Scientific, Inc.). Equivalent quantities of proteins (50 µg) harvested from CFs and conjunctival tissues were subjected to electrophoresis with 10% SDS-PAGE. Proteins were transferred onto polyviylidene difluoride membranes. Subsequently, the membranes were blocked at room temperature for 1 h using 5% not-fat milk in tris-buffered saline and incubated with primary antibodies against: α-smooth muscle actin (SMA; cat. no. ab5694), collagen 1 (cat. no. ab138492), fibronectin (FN)-1 (cat. no. ab2413; all Abcam, Cambridge, UK), β-actin (cat. no. 3700), collagen type 1 (Col1)α1 (cat. no. 84336), phosphorylated (p)-β-catenin (cat. no. 4176), β-catenin (cat. no. 8480), Lamin A/C (cat. no. 4777; all Cell Signaling Technology, Danvers, MA, USA) at 1:1,000 dilution and 4˚C overnight. The membranes were washed and then incubated with horseradish peroxidase-conjugated secondary antibodies (1:10,000; cat. no. ab6721; Abcam,) for 1 h at room temperature. Finally, an enhanced chemiluminescence ECL Detection kit (Thermo Fisher Scientific, Inc.) was utilized to evaluate the bands, and a transilluminator (Bio-Rad Laboratories, Inc., Hercules, CA, USA) was used to examine the intensity of the image.

Cell survival assessment

A cell counting kit-8 (CCK-8; Sigma-Aldrich; Merck KGaA) was used to assess survival. The media was replaced with fresh media with CCK-8 solution. Following a 2-h period of incubation at 37˚C, the microplate reader was used to spectrophotometrically assess absorbance at 450 nm.

Reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

TRIzol reagent (Invitrogen; Thermo Fisher Scientific, Inc.) was used to isolate total RNA from BCTs, which then underwent reverse transcription to cDNA using a First Stand cDNA synthesis kit (Sigma-Aldrich; Merck KGaA). qPCR was performed in triplicate using SYBR Premix Ex Taq (Takara Biotechnology Co., Ltd., Dalian, China) and SsoFast Probes Supermix (Bio-Rad Laboratories, Inc.). The following thermocycling conditions were used for the RT-qPCR: Initial denaturation at 95˚C for 1 min; 38 cycles for 95˚C for 1 min, 58˚C for 1 min, 72˚C for 1 min; and a terminal extension at 72˚C for 10 min. The outcome of RT-qPCR was evaluated using the 2-ΔΔCq approach (25) and was normalized in conformity with β-actin. The primers used were as follows: Col1α1, forward 5'-CCTCCCAGAACATTACATA-3' and reverse 5'-GACTGTCTTGCTCCATTCACCA-3'; FN-1, forward 5'-GACTCGTTTGACTTTGACTTCACCAC-3' and reverse 5'-GCTGAGACCCAGGAGACCAC-3'; collagen 1, forward 5'-TACAGCACGCTTGTGGATG-3' and reverse 5'-CAGATTGGGATGGAGGGAGTT-3'; α-SMA, forward 5'-GAGGCACCACTGAACCCTAA-3' and reverse 5'-CATCTCCAGAGTCCAGCACA-3'; β-catenin, forward 5'-GCTGACCTGATGGAGTTGGA-3' and reverse 5'-GCTACTTGCTCTTGCGTGAA-3'; and β-actin, forward 5'-GACGTTGACATCCGTAAAGACC-3' and reverse 5'-CTAGGAGCCAGGGCAGTAATCT-3'.

Hematoxylin and eosin (H&E) staining

H&E staining was carried out in 5-µm-thick paraffin-embedded sections of murine eye specimens, which were fixed with 4% paraformaldehyde at 25˚C for 30 min. The slices underwent deparaffinization (xylene, 3 min) and rehydration (100% ethanol, 3 min; 95% ethanol, 3 min; 70% ethanol, 3 min; 50% ethanol, 3 min) prior to H&E staining (1 min/each) for histopathological observation at 25˚C. A Nikon Diaphot 200 inverted microscope (Nikon Corporation, Tokyo, Japan) was used to evaluate images.

Statistical analysis

Data are presented as the mean ± standard deviation. Student's t-test was used to identify the significance of differences between two groups, and one-way analysis of variance followed by Tukey's test was used for analysis of multiple groups. P<0.05 was considered to indicate a statistically significant difference. GraphPad Prism IV software (GraphPad Software, Inc., La Jolla, CA, USA) was used for analyses.

Results

Chronic supplement of 0.01% ethylparaben induces murine bulbar SCF

In order to examine the influence of chronic supplementation of 0.01% ethylparaben on SCF in murine bulbar conjunctivas (BCs), the present study investigated slices of murine eye specimens that underwent H&E staining. H&E staining demonstrated that the density of fibroblasts was mildly promoted and the deposition of collagen was tighter in the subepithelium of BCs in the experimental group than the control group (Fig. 1). These findings suggested that chronic supplementation of ethylparaben triggered bulbar subconjunctival fibrosis (BSF).

Chronic supplementation of 0.01% ethylparaben enhances the expression of ECM in BCT

In order to verify that BSF triggered by chronic supplementation of 0.01% ethylparaben resulted from increased collagen production and other ECM material in BCTs, FN-1 and Col1α1 expression was evaluated in murine BCTs using WB. Expression of FN-1, Col1α1, collagen I and α-SMA were markedly promoted in the experimental group compared with the control group (Fig. 2A). The mRNA level of these genes was also promoted in the experimental group according to RT-qPCR (Fig. 2B).

Chronic supplementation of 0.01% ethylparaben activates the expression of agents linked with the Wnt/β-catenin axis in BCTs

It has been demonstrated previously that the Wnt/β-catenin axis participates in fibrosis (26,27). To explore the stimulation of the Wnt/β-catenin axis by chronic treatment with 0.01% ethylparaben, the expression of agents linked with the β-catenin pathway was explored in murine BCTs using WB. It was observed that both p- and total β-catenin levels were markedly upregulated in the ethylparaben-treated group compared with the control group (Fig. 3A), and that the β-catenin transcription was noticeably promoted in the experimental group according to RT-qPCR (Fig. 3B). These findings suggested that chronic supplementation of 0.01% ethylparaben was able to trigger stimulation of the Wnt/β-catenin axis, ECM overproduction and bringing about BSF.

Influence of ethylparaben on the expression of ECM and agents is associated with the Wnt/β-catenin axis in primary CFs

In order to reveal the etiology of SCF triggered by 0.01% ethylparaben, the influence of ethylparaben on the expression of ECM and agents linked with the Wnt/β-catenin axis in cultured murine primary CFs was explored.

In order to explore the influence of ethylparaben at low levels on CF survival, and to elucidate the optimal level of ethylparaben to reveal the etiology of the expression of ECM and agents linked with the Wnt/β-catenin axis, CFs were supplemented with media containing either ethylparaben or PBS for 24 h. The CCK-8 assay was used to evaluate survival. The cut-off concentration, 0.0001% is presented in Fig. 4A. Ethylparaben above this level was deleterious to CFs and suppressed CF survival. However, ethylparaben below this level did no significant damage to CFs. Consequently, 0.00005% ethylparaben was recognized as eligible for exploration of the etiology of expression of ECM and agents linked with the Wnt/β-catenin axis triggered by ethylparaben in CFs. It was demonstrated that the expression of FN-1, Col1α1, collagen I, α-SMA, total and p-β-catenin was markedly promoted 24 h following supplementation of CFs with 0.00005% ethylparaben (Fig. 4B). In addition, ethyparaben treatment promoted β-catenin translocation (Fig. 4C). These findings verified that ethylparaben at a low level did no damage to CFs and activated CF expression of ECM and agents linked with the Wnt/β-catenin axis.

Ethylparaben at a low level promotes the CF expression of ECM by stimulating the Wnt/β-catenin axis

To evaluate whether ECM gene expression was triggered by Wnt/β-catenin stimulation via low levels of ethylparaben in CFs, CFs were supplemented with ethylparaben, ethylparaben+XAV-939, or PBS. WB revealed that p-β-catenin expression was markedly promoted in the experimental group compared with the control group. However, p-β-catenin concentration was markedly downregulated in CFs that received ethylparaben+XAV-939 compared with those that received ethylparaben (Fig. 5A). Similarly, FN-1, Col1α1, collagen I and α-SMA expression were markedly suppressed in CFs that received ethylparaben+XAV-939 compared with those that received ethylparaben (Fig. 5B). These findings suggested that ethylparaben at low levels triggered the expression of ECM by stimulation of the Wnt/β-catenin axis in CFs.

Discussion

In the present study, it was demonstrated for the first time that ethylparaben-induced SCF was caused by the Wnt/β-catenin signaling pathway, to the best of our knowledge. Increased density of fibroblasts and deposition of collagen in subconjunctival tissue likely accounts for SCF (28,29). The present study initially revealed that chronic ethylparaben supplementation mildly promoted fibroblast density and induced tighter deposition of collagen in murine BST. Chronic ethylparaben supplementation markedly promoted ECM gene expression and stimulated the Wnt/β-catenin axis in murine BCT. Low levels of ethylparaben did no marked harm to cultivated CFs, but promoted ECM gene expression and triggered the Wnt/β-catenin axis. The ECM gene expression triggered via ethylparaben was impaired by the Wnt/β-catenin inhibitor, XAV-939. These findings elucidate the etiology of SCF triggered by ethylparaben.

Ethylparaben at a low level potentially serves as a xenobiotic to promote ECM gene expression in CFs by stimulation of the Wnt/β-catenin axis, which may be an extra side effect of ethylparaben on the conjunctiva. In investigation of ethylparaben toxicity, cell cultivation in vitro supplements animal experiments in vivo, despite the fact that cell monolayer fails to simulate the more complicated tissue structure. The cultivated cells are widely used to explore the influence of ethylparaben on the conjunctiva (30). Several objective standards are utilized to assess ethylparaben toxicity on cultivated cells such as survival, condensation of chromatin, ROS generation, and transmembrane mitochondrial potential (31-33). In order to determine the nontoxic influence of ethylparaben on CTs below the cutoff level, primary cultivated CFs were supplemented with ethylparaben for 24 h. It was demonstrated that ethylparaben did no harm to CFs, but mildly promoted CF proliferation. Supplementation of ethylparaben at a low level in the long-term likely accounts for CFs. Animal experiments were repeated, and the same results were obtained. Future studies will focus on how ethylparaben regulates the Wnt/β-catenin signaling pathway, and the protective effect of Wnt/β-catenin signaling pathway inhibition on ethylparaben-induced subconjunctival fibrosis.

In summary, the present study revealed that SCF triggered by ethylparaben results from stimulation of the Wnt/β-catenin axis in CFs. These findings also suggest that the development of ethylparaben-free eye drops may be necessary for patients and will also contribute to the development of novel therapeutic agents for ethylparaben-related ocular diseases.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and material

All data generated or analyzed during this study are included in this published article.

Authors' contributions

FGL and XFK conceived the study and designed the experiments, XFK and HK contributed to the data collection, performed the data analysis and interpreted the results. FGL wrote the manuscript; XFK contributed to the critical revision of article. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The present study was approved by the Committee on the Ethics of Animal Experiments at Zoucheng People's Hospital (Zoucheng, China).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Final amended report on the safety assessment of Methylparaben, Ethylparaben, Propylparaben, Isopropylparaben, Butylparaben, Isobutylparaben and Benzylparaben as used in cosmetic products. Int J Toxicol. 27 (Suppl 4):S1–S82. 2008.PubMed/NCBI View Article : Google Scholar

2 

Kolatorova L, Vitku J, Hampl R, Adamcova K, Skodova T, Simkova M, Parizek A, Starka L and Duskova M: Exposure to bisphenols and parabens during pregnancy and relations to steroid changes. Environ Res. 163:115–122. 2018.PubMed/NCBI View Article : Google Scholar

3 

Huang C, Wang H, Pan J, Zhou D, Chen W, Li W, Chen Y and Liu Z: Benzalkonium chloride induces subconjunctival fibrosis through the COX-2-modulated activation of a TGF-β1/Smad3 signaling pathway. Invest Ophthalmol Vis Sci. 55:8111–8122. 2014.PubMed/NCBI View Article : Google Scholar

4 

Yalniz-Akkaya Z, Simsek GG, Uney GO, Burcu A and Ornek F: Effect of cauterization on the subconjunctival fibrovascular reaction in rabbit eyes. Semin Ophthalmol. 30:202–205. 2015.PubMed/NCBI View Article : Google Scholar

5 

Paula JS, Ribeiro VR, Chahud F, Cannellini R, Monteiro TC, Gomes EC, Reinach PS, Rodrigues Mde L and Silva-Cunha A: Bevacizumab-loaded polyurethane subconjunctival implants: Effects on experimental glaucoma filtration surgery. J Ocul Pharmacol Ther. 29:566–573. 2013.PubMed/NCBI View Article : Google Scholar

6 

Zhan T, Rindtorff N and Boutros M: Wnt signaling in cancer. Oncogene. 36:1461–1473. 2017.PubMed/NCBI View Article : Google Scholar

7 

Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 127:469–480. 2006.PubMed/NCBI View Article : Google Scholar

8 

Krishnamurthy N and Kurzrock R: Targeting the Wnt/beta-catenin pathway in cancer: Update on effectors and inhibitors. Cancer Treat Rev. 62:50–60. 2018.PubMed/NCBI View Article : Google Scholar

9 

Zhu X, Yuan C, Tian C, Li C, Nie F, Song X, Zeng R, Wu D, Hao X and Li L: The plant sesquiterpene lactone parthenolide inhibits Wnt/β-catenin signaling by blocking synthesis of the transcriptional regulators TCF4/LEF1. J Biol Chem. 293:5335–5344. 2018.PubMed/NCBI View Article : Google Scholar

10 

Feng XY, Wu XS, Wang JS, Zhang CM and Wang SL: Homeobox protein MSX-1 inhibits expression of bone morphogenetic protein 2, bone morphogenetic protein 4, and lymphoid enhancer-binding factor 1 via Wnt/β-catenin signaling to prevent differentiation of dental mesenchymal cells during the late bell stage. Eur J Oral Sci. 126:1–12. 2018.PubMed/NCBI View Article : Google Scholar

11 

Tacchelly-Benites O, Wang Z, Yang E, Benchabane H, Tian A, Randall MP and Ahmed Y: Axin phosphorylation in both Wnt-off and Wnt-on states requires the tumor suppressor APC. PLoS Genet. 14(e1007178)2018.PubMed/NCBI View Article : Google Scholar

12 

Emerick B, Schleiniger G and Boman BM: A kinetic model to study the regulation of beta-catenin, APC, and Axin in the human colonic crypt. J Math Biol. 75:1171–1202. 2017.PubMed/NCBI View Article : Google Scholar

13 

Pecina-Slaus N, Kafka A, Vladusic T, Pecina HI and Hrascan R: AXIN1 expression and localization in meningiomas and association to changes of APC and E-cadherin. Anticancer Res. 36:4583–4594. 2016.PubMed/NCBI View Article : Google Scholar

14 

Niu C, Yin L and Aisa HA: Novel furocoumarin derivatives stimulate melanogenesis in B16 melanoma cells by up-regulation of MITF and TYR family via Akt/GSK3β/β-catenin signaling pathways. Int J Mol Sci. 19(E746)2018.PubMed/NCBI View Article : Google Scholar

15 

Mbom BC, Siemers KA, Ostrowski MA, Nelson WJ and Barth AI: Nek2 phosphorylates and stabilizes β-catenin at mitotic centrosomes downstream of Plk1. Mol Biol Cell. 25:977–991. 2014.PubMed/NCBI View Article : Google Scholar

16 

Dijksterhuis JP, Baljinnyam B, Stanger K, Sercan HO, Ji Y, Andres O, Rubin JS, Hannoush RN and Schulte G: Systematic mapping of WNT-FZD protein interactions reveals functional selectivity by distinct WNT-FZD pairs. J Biol Chem. 290:6789–6798. 2015.PubMed/NCBI View Article : Google Scholar

17 

Endo Y, Beauchamp E, Woods D, Taylor WG, Toretsky JA, Uren A and Rubin JS: Wnt-3a and Dickkopf-1 stimulate neurite outgrowth in ewing tumor cells via a Frizzled3- and c-Jun N-terminal kinase-dependent mechanism. Mol Cell Biol. 28:2368–2379. 2008.PubMed/NCBI View Article : Google Scholar

18 

Lietman C, Wu B, Lechner S, Shinar A, Sehgal M, Rossomacha E, Datta P, Sharma A, Gandhi R, Kapoor M and Young PP: Inhibition of Wnt/β-catenin signaling ameliorates osteoarthritis in a murine model of experimental osteoarthritis. JCI Insight. 3(96308)2018.PubMed/NCBI View Article : Google Scholar

19 

Jeon KI, Phipps RP, Sime PJ and Huxlin KR: Antifibrotic actions of peroxisome proliferator-activated receptor gamma ligands in corneal fibroblasts are mediated by β-catenin-regulated pathways. Am J Pathol. 187:1660–1669. 2017.PubMed/NCBI View Article : Google Scholar

20 

Kato N, Shimmura S, Kawakita T, Miyashita H, Ogawa Y, Yoshida S, Higa K, Okano H and Tsubota K: Beta-catenin activation and epithelial-mesenchymal transition in the pathogenesis of pterygium. Invest Ophthalmol Vis Sci. 48:1511–1517. 2007.PubMed/NCBI View Article : Google Scholar

21 

ARVO statement on registering clinical trials. Invest Ophthalmol Vis Sci. 47:1–2. 2006.PubMed/NCBI View Article : Google Scholar

22 

Tong J, Zheng X, Tan X, Fletcher R, Nikolovska-Coleska Z, Yu J and Zhang L: Mcl-1 phosphorylation without degradation mediates sensitivity to HDAC inhibitors by liberating BH3-only proteins. Cancer Res. 78:4704–4715. 2018.PubMed/NCBI View Article : Google Scholar

23 

Tong J, Wang P, Tan S, Chen D, Nikolovska-Coleska Z, Zou F, Yu J and Zhang L: Mcl-1 degradation is required for targeted therapeutics to eradicate colon cancer cells. Cancer Res. 77:2512–2521. 2017.PubMed/NCBI View Article : Google Scholar

24 

Brown KD, Shah MH, Liu GS, Chan EC, Crowston JG and Peshavariya HM: Transforming growth factor β1-induced NADPH oxidase-4 expression and fibrotic response in conjunctival fibroblasts. Invest Ophthalmol Vis Sci. 58:3011–3017. 2017.PubMed/NCBI View Article : Google Scholar

25 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.PubMed/NCBI View Article : Google Scholar

26 

Chen L, Tang RZ, Ruan J, Zhu XB and Yang Y: Up-regulation of THY1 attenuates interstitial pulmonary fibrosis and promotes lung fibroblast apoptosis during acute interstitial pneumonia by blockade of the WNT signaling pathway. Cell Cycle. 4:1–12. 2019.PubMed/NCBI View Article : Google Scholar

27 

Shao X and Wei X: FOXP1 enhances fibrosis via activating Wnt/β-catenin signaling pathway in endometriosis. Am J Transl Res. 10:3610–3618. 2018.PubMed/NCBI

28 

Garcia-Posadas L, Soriano-Romani L, Lopez-Garcia A and Diebold Y: An engineered human conjunctival-like tissue to study ocular surface inflammatory diseases. PLoS One. 12(e0171099)2017.PubMed/NCBI View Article : Google Scholar

29 

Ekinci M, Cagatay HH, Ceylan E, Keles S, Koban Y, Gokce G, Huseyinoğlu U, Ozcan E and Oba ME: Reduction of conjunctival fibrosis after trabeculectomy using topical α-lipoic acid in rabbit eyes. J Glaucoma. 23:372–379. 2014.PubMed/NCBI View Article : Google Scholar

30 

Takahashi N: Quantitative cytotoxicity of preservatives evaluated in cell culture with Chang's human conjunctival cells-effect of temperature on cytotoxicity. Jpn J Ophthalmol. 26:234–238. 1982.PubMed/NCBI

31 

Martins RC, Gmurek M, Rossi AF, Corceiro V, Costa R, Quinta-Ferreira ME, Ledakowicz S and Quinta-Ferreira RM: Application of fenton oxidation to reduce the toxicity of mixed parabens. Water Sci Technol. 74:1867–1875. 2016.PubMed/NCBI View Article : Google Scholar

32 

Liu T, Li Y, Zhao X, Zhang M and Gu W: Ethylparaben affects lifespan, fecundity, and the expression levels of ERR, EcR and YPR in drosophila melanogaster. J Insect Physiol. 71:1–7. 2014.PubMed/NCBI View Article : Google Scholar

33 

Vad NM, Shaik IH, Mehvar R and Moridani MY: Metabolic bioactivation and toxicity of ethyl 4-hydroxybenzoate in human SK-MEL-28 melanoma cells. J Pharm Sci. 97:1934–1945. 2008.PubMed/NCBI View Article : Google Scholar

Related Articles

Journal Cover

April-2021
Volume 21 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Liu F, Kong X and Kong H: Ethylparaben induces subconjunctival fibrosis via the Wnt/β‑catenin signaling pathway. Exp Ther Med 21: 295, 2021
APA
Liu, F., Kong, X., & Kong, H. (2021). Ethylparaben induces subconjunctival fibrosis via the Wnt/β‑catenin signaling pathway. Experimental and Therapeutic Medicine, 21, 295. https://doi.org/10.3892/etm.2021.9726
MLA
Liu, F., Kong, X., Kong, H."Ethylparaben induces subconjunctival fibrosis via the Wnt/β‑catenin signaling pathway". Experimental and Therapeutic Medicine 21.4 (2021): 295.
Chicago
Liu, F., Kong, X., Kong, H."Ethylparaben induces subconjunctival fibrosis via the Wnt/β‑catenin signaling pathway". Experimental and Therapeutic Medicine 21, no. 4 (2021): 295. https://doi.org/10.3892/etm.2021.9726